Sharon Prince

Prof. Sharon Prince

University of Cape Town, South Africa
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2022 in Tumour Virus Research
Verified
Journal Article
Open access
CBCarly A. Burmeister
Carly A. Burmeister
SKSaif F. Khan
Saif F. Khan
Georgia SchäferGeorgia Schäfer
Georgia Schäfer
NMNomonde Mbatani
Nomonde Mbatani
TATracey Adams
Tracey Adams
Sharon PrinceSharon Prince
Sharon Prince
Cervical cancer is the fourth most common female cancer worldwide and results in over 300 000 deaths globally. The causative agent of cervical cancer is persistent infection with high-risk subtypes of the human papillomavirus and the E5, E6 and E7 viral oncoproteins cooperate with host factors to induce and maintain the malignant phenotype. Cervical cancer is a largely preventable disease and early-stage detection is associated with significantly improved survival rates. Indeed, in high-income countries with established vaccination and screening programs it is a rare disease. However, the disease is a killer for women in low- and middle-income countries who, due to limited resources, often present with advanced and untreatable disease. Treatment options include surgical interventions, chemotherapy and/or radiotherapy either alone or in combination. This review describes the initiation and progression of cervical cancer and discusses in depth the advantages and challenges faced by current cervical cancer therapies, followed by a discussion of promising and efficacious new therapies to treat cervical cancer including immunotherapies, targeted therapies, combination therapies, and genetic treatment approaches.

30 June 2021 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
VDVictoria Damerell
Victoria Damerell
Michael Sean PepperMichael Sean Pepper
Michael Sean Pepper
Sharon PrinceSharon Prince
Sharon Prince
Sarcomas are complex mesenchymal neoplasms with a poor prognosis. Their clinical management is highly challenging due to their heterogeneity and insensitivity to current treatments. Although there have been advances in understanding specific genomic alterations and genetic mutations driving sarcomagenesis, the underlying molecular mechanisms, which are likely to be unique for each sarcoma subtype, are not fully understood. This is in part due to a lack of consensus on the cells of origin, but there is now mounting evidence that they originate from mesenchymal stromal/stem cells (MSCs). To identify novel treatment strategies for sarcomas, research in recent years has adopted a mechanism-based search for molecular markers for targeted therapy which has included recapitulating sarcomagenesis using in vitro and in vivo MSC models. This review provides a comprehensive up to date overview of the molecular mechanisms that underpin sarcomagenesis, the contribution of MSCs to modelling sarcomagenesis in vivo, as well as novel topics such as the role of epithelial-to-mesenchymal-transition (EMT)/mesenchymal-to-epithelial-transition (MET) plasticity, exosomes, and microRNAs in sarcomagenesis. It also reviews current therapeutic options including ongoing pre-clinical and clinical studies for targeted sarcoma therapy and discusses new therapeutic avenues such as targeting recently identified molecular pathways and key transcription factors.

1 March 2010 in Genes & Cancer
Verified
Journal Article
Open access
PDF file
JPJade Peres
Jade Peres
EDEmily Davis
Emily Davis
SMShaheen Mowla
Shaheen Mowla
DBDorothy C. Bennett
Dorothy C. Bennett
JLJarod A. Li
Jarod A. Li
Sharon PrinceSharon Prince
Sharon Prince
The T-box transcription factors TBX2 and TBX3 are overexpressed in several cancers and are able to bypass senescence by repressing ARF and p21WAF1/CIP1/SDII. Although these studies suggest that they may both contribute to the oncogenic process by repressing common targets, whether they have redundant or distinct roles in cancers where they are both overexpressed remains to be elucidated. Importantly, when Tbx2 function is inhibited in melanoma cells lacking Tbx3, the cells senesce, but whether this is possible in melanoma cells overexpressing both proteins is not known. An understanding of this issue may have important implications for the design of an effective pro-senescence therapy. In this study, the authors used a sh-RNA approach to knock down TBX2 and TBX3 individually in 2 human melanoma cell lines that overexpress both these factors and then examined their specific involvement in the oncogenic process. They demonstrate, using in vitro and in vivo cell proliferation, as well as colony- and tumor-forming ability and cell motility assays, that TBX2 and TBX3 have distinct roles in melanoma progression. In the tested lines, although TBX2 could promote proliferation and transformation and was required by primary melanoma cells for immortality, TBX3 was required for tumor formation and cell migration. These findings were reproducible in a human breast cancer cell line, which confirms that TBX2 and TBX3, although highly homologous, do not have redundant roles in the transformation process of cancers where they are both overexpressed. These results have important implications for the development of new cancer treatments and in particular for melanoma, which is a highly aggressive and intractable cancer.

3 December 2009 in IUBMB Life
Verified
Journal Article
Closed access
PDF file
AAAmaal Abrahams
Amaal Abrahams
MPM. Iqbal Parker
M. Iqbal Parker
Sharon PrinceSharon Prince
Sharon Prince

1 February 2020 in Gene
Verified
Journal Article
Closed access
SKSaif F. Khan
Saif F. Khan
VDVictoria Damerell
Victoria Damerell
RORehana Omar
Rehana Omar
MTMichelle Du Toit
Michelle Du Toit
MKMohsin Khan
Mohsin Khan
Sharon PrinceSharon Prince
Sharon Prince

1 January 2013 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
JPJade Peres
Jade Peres
Sharon PrinceSharon Prince
Sharon Prince
The T-box transcription factor, TBX3, is overexpressed in several cancers and has been proposed as a chemotherapeutic target. Several lines of evidence suggest that TBX3 may be a key contributor to malignant melanoma, a highly aggressive and intractable disease. Using in vitro and in vivo assays we demonstrate here for the first time that overexpressing TBX3 in non-tumourigenic early stage melanoma cells is sufficient to promote tumour formation and invasion. Furthermore, we show that TBX3 may play an important role as a reciprocal switch between substrate dependent cell proliferation and tumour invasion.